U.S. Markets closed

Erasca, Inc. (ERAS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.010.00 (0.00%)
At close: 01:00PM EST
7.36 +0.36 (+5.16%)
After hours: 01:19PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.01
Bid6.99 x 900
Ask11.24 x 900
Day's Range6.91 - 7.46
52 Week Range4.51 - 16.34
Avg. Volume711,288
Market Cap849.962M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks

    Wall Street Analysts Predict a 126% Upside in Erasca, Inc. (ERAS): Here's What You Should Know

    The average of price targets set by Wall Street analysts indicates a potential upside of 125.9% in Erasca, Inc. (ERAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • Benzinga

    Erasca Touts Promising Early Data From Lead Cancer Programs

    Erasca Inc (NASDAQ: ERAS) announced preliminary Phase 1/1b monotherapy data for ERAS-007 and ERAS-601 in solid tumor settings. A retrospective pooled analysis of all trials evaluating ERAS-007 or ERAS-601 in advanced solid tumors included Erasca's ongoing HERKULES-1 and FLAGSHP-1 trials and Asana BioSciences' previously completed ASN007-101 trial. Key findings from the retrospective pooled interim analysis of ERAS-007 and ERAS-601 show that 23% (6/26) of patients with RAS/MAPK-altered non-colore

  • Zacks

    Here's Why Erasca, Inc. (ERAS) Looks Ripe for Bottom Fishing

    Erasca, Inc. (ERAS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.